Landing Forty Two in London provided a fitting backdrop for Colgate®’s recent thought leadership event, Partnering for Prevention: From Evidence into Action. The event brought together dental professionals from across the UK for an inspiring networking event, exploring how to bridge the gap between clinical and chairside reality.
The audience heard insights from a range of stakeholders focusing on caries prevention including moving beyond clinical data to put them into their patients shoes to better understand real world challenges. Simon Petersen, Senior Vice President and General Manager at Colgate®, Northern Europe welcomed the audience, sharing that Colgate®’s leadership position is driven by their purpose of reimagining a healthier future for all. Simon said Colgate® understands the significance and importance of evidence-based prevention and Delivering Better Oral Health guidance; including increasing fluoride availability and stating that Colgate® is proud to have supported the dental profession with medically licensed evidence-based high fluoride products to prevent, control and arrest caries. Simon concluded that he was delighted Colgate® had brought together insights from the dental profession, consumers, researchers and academia to explore prevention and how we best translate evidence into action to improve oral health.
Dr Jason Wong, Chief Dental Officer, England gave the opening keynote address themed ‘A call to action to improve the oral health of the nation’, sharing updates on the 10-year health plan and the dental quality and payment reforms. This included increased support for preventive care, risk assessment and oral health stabilisation, promotion of good quality evidence-based care, minimally intervention oral care and the appropriate use of skill mix. Jason commented that he was aligned with the theme ‘Partnering for Prevention’ and supported the shared vision of taking knowledge, evidence and the right people delivering care at the right time to improve the oral health of the nation.
Katie Mitchell, Senior Insights Lead at Colgate®, explored three pathways of prevention. Katie introduced the views and perceptions of real world patients who had been unsuccessful, partially successful and fully successful across the pathways. This took the audience through the resulting impact of each, along with the patients suggestions of how their real world challenges could be better overcome to help them to improve both their compliance and oral health outcome.
Professor Jan Clarkson, Chair of Clinical Effectiveness, University of Dundee shared the REFLECT study, a NIHR clinical trial, which commenced back in 2016, looking at the effectiveness and cost benefit of prescribing high dose fluoride toothpaste in preventing and treating dental caries in high-risk older adults. The results are expected to be published later this year. However, Jan was able to share some key points including: dentists can identify patients at risk, caries experience is considerable and costly, 5000ppm fluoride toothpaste is part of the solution, however dentists must know who, when and how much to prescribe, and finally, patient behaviour change is possible, but this must be personalised and focus on oral hygiene and diet.
Professor Jo Hart, Chair of Health Professional Education, University of Manchester explored professional behaviour change to better understand clinical habits. Jo expressed how hard change can be and for change to happen, it needs to happen at multiple levels including dental professionals, patients and policy makers. Jo shared the Capability, Opportunity, and Motivation Behaviour (COM-B) framework as part of the Behaviour Change Wheel. This helps us to understand that unless what we do is behaviourally focused, it is less likely to change routine practice. Capability, motivation and opportunity must be enhanced to change practice.
This event brought together a group of insightful contributors covering expertise across contract reform, research, skill mix, behaviour change and general dental practice. A fireside chat session created the perfect opportunity to discuss a number of themes to help transform insights into a tangible road map for the entire dental team including keeping healthy teeth healthy across the life course, applying the evidence base in practice, the role of prevention in supporting the shift from treatment-focused to prevention-led care and the effective use of skill mix.
The final session was delivered by Emma van Eyssen, Scientific Affairs Lead at Colgate® and Dr Mohsan Ahmad, General Dentist and LDN Chair for Greater Manchester. Emma started the session with highlighting a number of resources Colgate® provides to help dental professionals with the prevention, management and control of caries, in line with the evidence-base. Emma went onto introduce Colgate® Duraphat® as the only complete and clinically-proven high-fluoride range, medicinally licensed to prevent, control and arrest caries.1-4 Mohsan then took the audience through some real life cases studies on how he and his wider dental team provide individually tailored optimal care for the prevention, management and control of caries across the life course.
The event concluded with a lively networking session allowing for great discussion which perfectly captured Mohsan’s final comment that together, we can shape the future of oral health.
For more information, please click here.
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk.
Adverse events should also be reported to Colgate-Palmolive (U.K.) by calling 00-800-321-321-32
References:
- Baysan A et al. Caries Res 2001;35:41-46, 2. Schirrmeister JF et al. Am J Dent 2007;20. 212-216, 3. Ekstrand et al. 2008 Gerod 2008; 25:67-75, 4. Ekstrand et al. Caries Res 2013;47:391–8.
Prescribing Information:
Name of the medicinal product: Duraphat® 50mg/ml Dental Suspension. Active ingredients: 1ml of suspension contains 50mg Sodium Fluoride equivalent to 22.6mg of Fluoride (22,600 ppm F-) Indications: Prevention of caries, desensitisation of hypersensitive teeth. Dosage and administration: Recommended dosage for single application: for milk teeth: up to 0.25ml (=5.65mg Fluoride), for mixed dentition: up to 0.40ml (=9.04 Fluoride), for permanent dentition: up to 0.75ml (=16.95 Fluoride). For caries prophylaxis the application is usually repeated every 6 months but more frequent applications (every 3 months) may be made. For hypersensitivity, 2 or 3 applications should be made within a few days. Contraindications: Hypersensitivity to colophony and/or any other constituents. Ulcerative gingivitis. Stomatitis. Bronchial asthma. Special warnings and special precautions for use: If the whole dentition is being treated the application should not be carried out on an empty stomach. On the day of application other high fluoride preparations such a fluoride gel should be avoided. Fluoride supplements should be suspended for several days after applying Duraphat®. Interactions with other medicines: The presence of alcohol in the Duraphat® formula should be considered. Undesirable effects: Oedematous swelling has been observed in subjects with tendency to allergic reactions. The dental suspension layer can easily be removed from the mouth by brushing and rinsing. In rare cases, asthma attacks may occur in patients who have bronchial asthma. Legal classification: POM. Product licence number: PL 00049/0042. Product licence holder: Colgate-Palmolive (U.K.) Ltd. Guildford Business Park, Midleton Road, Guildford, Surrey, GU2 8JZ. Price: £22.70 excl VAT (10ml tube) Date of revision of text: November 2022.
Name of the medicinal product: Duraphat® 5000 ppm Fluoride Toothpaste. Active ingredient: Sodium Fluoride 1.1%w/w (5000ppm F-). 1g of toothpaste contains 5mg fluoride (as sodium fluoride), corresponding to 5000ppm fluoride. Indications: For the prevention of dental caries in adolescents and adults 16 years of age and over, particularly amongst patients at risk from multiple caries (coronal and/or root caries). Dosage and administration: Brush carefully on a daily basis applying a 2cm ribbon onto the toothbrush for each brushing. 3 times daily, after each meal. Contraindications: This medicinal product must not be used in cases of hypersensitivity to the active substance or to any of the excipients. Special warnings and precautions for use: An increased number of potential fluoride sources may lead to fluorosis. Before using fluoride medicines such as Duraphat, an assessment of overall fluoride intake (i.e. drinking water, fluoridated salt, other fluoride medicines – tablets, drops, gum or toothpaste) should be done. Fluoride tablets, drops, chewing gum, gels or varnishes and fluoridated water or salt should be avoided during use of Duraphat Toothpaste. When carrying out overall calculations of the recommended fluoride ion intake, which is 0.05mg/kg per day from all sources, not exceeding 1mg per day, allowance must be made for possible ingestion of toothpaste (each tube of Duraphat 500mg/100g Toothpaste contains 255mg of fluoride ions). This product contains Sodium Benzoate. Sodium Benzoate is a mild irritant to the skin, eyes and mucous membrane. Undesirable effects: Gastrointestinal disorders: Frequency not known (cannot be estimated from the available data): Burning oral sensation. Immune system disorders: Rare (≥1/10,000 to <1/1,000): Hypersensitivity reactions. Legal classification: POM. Marketing authorisation number: PL00049/0050. Marketing authorisation holder: Colgate-Palmolive (U.K.) Ltd. Guildford Business Park, Midleton Road, Guildford, Surrey, GU2 8JZ. Recommended retail price: £7.99 (51g tube). Date of revision of text: July 2022.
Name of the medicinal product: Duraphat® 2800 ppm Fluoride Toothpaste. Active ingredient: Sodium Fluoride 0.619 %w/w (2800 ppm F-). Indications: For the prevention and treatment of dental caries (coronal and root) in adults and children 10 years of age and over. Dosage and administration: Use daily instead of normal toothpaste. Apply a 1cm line of paste across the head of a toothbrush and brush the teeth thoroughly for one minute morning and evening. Spit out after use; for best results do not drink or rinse for 30 minutes. Contraindications: Individuals with known sensitivities should consult their dentist before using. Not to be used in children under 10 years old. Special warnings and precautions for use: Not to be swallowed. Undesirable effects: When used as recommended there are no side effects. Legal classification: POM. Marketing authorisation number: PL00049/0039. Marketing authorisation holder: Colgate-Palmolive (U.K.) Ltd. Guildford Business Park, Midleton Road, Guildford, Surrey, GU2 8JZ. Recommended retail price: £5.10 (75ml tube). Date of revision of text: September 2022.
